Trial Profile
Personalized Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic During Chemotherapy: A GETUG-AFU 28 Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms TACTIK
- 09 Feb 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2021 Planned End Date changed from 31 Jul 2021 to 31 Dec 2021.
- 27 Sep 2021 Planned primary completion date changed from 31 Jul 2021 to 31 Dec 2021.